These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21516078)

  • 1. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.
    Ching CB; Amin MB; Tubbs RR; Elson P; Platt E; Dreicer R; Fergany A; Hansel DE
    Mod Pathol; 2011 Aug; 24(8):1111-9. PubMed ID: 21516078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
    Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
    Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
    Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
    Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
    Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
    Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.
    Kim B; Kim G; Song B; Lee C; Park JH; Moon KC
    Dis Markers; 2016; 2016():8463731. PubMed ID: 27034533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
    Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.
    Tschui J; Vassella E; Bandi N; Baumgartner U; Genitsch V; Rotzer D; Seiler R; Thalmann GN; Fleischmann A
    Virchows Arch; 2015 Jun; 466(6):703-10. PubMed ID: 25809292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
    Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.
    Stewart RL; Caron JE; Gulbahce EH; Factor RE; Geiersbach KB; Downs-Kelly E
    Mod Pathol; 2017 Nov; 30(11):1561-1566. PubMed ID: 28752841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?
    Prendeville S; Corrigan MA; Livingstone V; Feeley L; Bennett MW; Browne TJ; O'Connell F
    Am J Clin Pathol; 2016 Mar; 145(3):316-22. PubMed ID: 27124913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-erb-2 gene amplification and chromosomal anomalies in bladder cancer: preliminary results.
    Leonardo C; Merola R; Orlandi G; Leonardo F; Rondoni M; De Nunzio C
    J Exp Clin Cancer Res; 2005 Dec; 24(4):633-8. PubMed ID: 16471327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    Bartlett JM; Campbell FM; Mallon EA
    Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique.
    Langner C; Gross C; Rehak P; Ratschek M; Rüschoff J; Zigeuner R
    Urology; 2005 Jan; 65(1):176-80. PubMed ID: 15667899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.